These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21566327)

  • 1. Effect of the quality of water used for dialysis on the efficacy of hemodialysis: a single-center experience from Morocco.
    Akhmouch I; Asserraji M; Bahadi A; Bouaiti E; Alayoude M; Aatif T; Hamzi MA; Kawtar H; Allam M; Oualim Z
    Saudi J Kidney Dis Transpl; 2011 May; 22(3):576-80. PubMed ID: 21566327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study.
    Hsu PY; Lin CL; Yu CC; Chien CC; Hsiau TG; Sun TH; Huang LM; Yang CW
    J Nephrol; 2004; 17(5):693-700. PubMed ID: 15593037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of high-flux hemodialysis on renal anemia.
    Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
    J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What happens after conversion of treatment to continuous ambulatory peritoneal dialysis from hemodialysis?
    Sezer S; Ozdemir N; Arat Z; Güz G; Sengül S; Akman B; Haberal A; Turan M; Haberal M
    Adv Perit Dial; 2000; 16():177-81. PubMed ID: 11045288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality.
    Korevaar JC; van Manen JG; Dekker FW; de Waart DR; Boeschoten EW; Krediet RT;
    J Am Soc Nephrol; 2004 Nov; 15(11):2916-22. PubMed ID: 15504945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum albumin, body weight and inflammatory parameters in chronic hemodialysis patients: a three-year longitudinal study.
    Bossola M; La Torre G; Giungi S; Tazza L; Vulpio C; Luciani G
    Am J Nephrol; 2008; 28(3):405-12. PubMed ID: 18087147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.
    Locatelli F; Andrulli S; Memoli B; Maffei C; Del Vecchio L; Aterini S; De Simone W; Mandalari A; Brunori G; Amato M; Cianciaruso B; Zoccali C
    Nephrol Dial Transplant; 2006 Apr; 21(4):991-8. PubMed ID: 16384825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nutritional status, comorbidity, and inflammation in hemodialysis].
    Fernández-Reyes MJ; Alvarez-Ude F; Sánchez R; Mon C; Iglesias P; Vázquez A
    Nefrologia; 2000; 20(6):540-9. PubMed ID: 11217649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
    Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
    Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of care assessment and adherence to the international guidelines considering dialysis, water treatment, and protection against transmission of infections in university hospital-based dialysis units in Cairo, Egypt.
    Ibrahim S
    Hemodial Int; 2010 Jan; 14(1):61-7. PubMed ID: 19758297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sodium balance and the combination of ultrafiltration profile during sodium profiling hemodialysis on the maintenance of the quality of dialysis and sodium and fluid balances.
    Song JH; Park GH; Lee SY; Lee SW; Lee SW; Kim MJ
    J Am Soc Nephrol; 2005 Jan; 16(1):237-46. PubMed ID: 15563561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy.
    Sirken G; Kung SC; Raja R
    ASAIO J; 2003; 49(4):422-5. PubMed ID: 12918584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intradialytic intravenous administration of omega-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: a pilot study.
    Szklarek-Kubicka M; Fijałkowska-Morawska J; Zaremba-Drobnik D; Uciński A; Czekalski S; Nowicki M
    J Ren Nutr; 2009 Nov; 19(6):487-93. PubMed ID: 19616450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic inflammation, oxidative stress and effects of erythropoetin in end-stage renal disease patients].
    Lazarević T; Stojimirović B; Poskurica M; Lazarević M; Mitrović N; Stolić R
    Med Pregl; 2007; 60 Suppl 2():109-13. PubMed ID: 18928173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.